Overview

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease. We hope to learn more about the causes of lung disease in cystic fibrosis by studying the characteristics of the inflammation in the lungs of patients who have CF.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Collaborators:

Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics

Treatments:

Acetylcysteine
N-monoacetylcystine